Results 141 to 150 of about 101,548 (353)

Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists : a real-world study in 66 583 patients [PDF]

, 2017
Background Real world outcomes of addition or switch to insulin therapy in type 2 diabetes (T2DM) patients on glucagon-like paptide-1 receptor agonist (GLP-1RA) with inadequately controlled hyperglycaemia, are not known.
American Diabetes Association, Balena, Balkau, Crawford, Davis, Drucker, Eng, Fox, Garber, Gautier, Inzucchi, Kamal, Khunti, Lee, Li, Monami, Paul, Paul, Paul, Rigato, Shaefer, Shah, Smilowitz, Thong, Turnbull, Vora   +25 more
core   +1 more source

Trends in Glucagon-like Peptide 1 Receptor Agonist Use, 2014 to 2022.

Journal of the American Pharmacists Association, 2023
Jonathan H. Watanabe, Jimmy Kwon, Bin Nan, Andrew Reikes   +3 more
semanticscholar   +1 more source

Expanding the genotypic spectrum of PCSK1 deficiency: A novel mutation in severe neonatal diarrhea

JPGN Reports, EarlyView.
Abstract Among congenital diarrhea and enteropathies (CODEs), proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency is a rare monogenic disorder, associated with severe neonatal diarrhea and polyendocrinopathies. We report an 18‐day‐old male neonate, born to consanguineous parents, presenting with persistent watery diarrhea, metabolic ...
Eleonora Saraceno, Angelo Corso Faini, Silvia Deaglio, Marianna Pellegrini, Raffaele Buganza, Francesca Giuliani, Pier Luigi Calvo, Michele Pinon   +7 more
wiley   +1 more source

Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report

Journal of International Medical Research
Semaglutide is a glucagon-like peptide-1 receptor agonist used in the treatment of type 2 diabetes mellitus and management of obesity. Associations of glucagon-like peptide-1 receptor agonist use with psychiatric adverse events and suicidal behavior have
Anisija Stojkovska, Polona Rus Prelog, Anja Kokalj Palandacic   +2 more
doaj   +1 more source

Tirzepatide-induced ketoacidosis in non-diabetic patients

European Journal of Case Reports in Internal Medicine
Background: Tirzepatide is a novel glucagon-like peptide 1/glucose-dependent insulinotropic peptide (GLP-1/GIP) receptor agonist. It was recently approved for diabetes control and weight reduction in non-diabetic patients. Case description: We report the
Pathan Mohamad Rafe Iqbal, Ossama Sajeh Maadarani, Zouheir Ibrahim Bitar   +2 more
doaj   +1 more source

Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction‐associated steatotic liver disease treated with semaglutide: A case series

JPGN Reports, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects 30%–40% of youth with obesity and lacks approved pharmacologic therapies. In this single‐center retrospective case series at a tertiary care safety‐net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index:
Rachel Schenker, Katya Fomenko, Fotini T. Mitsinikos, Alaina P. Vidmar   +3 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP

Drug Design, Development and Therapy, 2023
Ping Fang,1 Zhengqin Ye,1 Ran Li,1 Dunmin She,2 Guannan Zong,1 Liya Zhang,1 Ying Xue,1 Keqin Zhang1 1Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, People’s Republic of China ...
Fang P, Ye Z, Li R, She D, Zong G, Zhang L, Xue Y, Zhang K   +7 more
doaj  

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source

Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans [PDF]

, 2018
Purpose: Radiolabelled glucagon-like peptide 1 (GLP-1) receptor agonists have recently been shown to successfully image benign insulinomas in patients.
Reubi, Jean, Waser, Beatrice
core  

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source